Asunto(s)
Acrilamidas/farmacología , Médula Ósea/efectos de los fármacos , Eritrocitos/efectos de los fármacos , Micronúcleos con Defecto Cromosómico/efectos de los fármacos , Mutágenos/farmacología , Acrilamida , Acrilamidas/administración & dosificación , Animales , Ciclofosfamida/farmacología , Relación Dosis-Respuesta a Droga , Esquema de Medicación , Eritrocitos/ultraestructura , Femenino , Masculino , Ratones , Ratones Endogámicos , Pruebas de Micronúcleos/métodos , Factores SexualesRESUMEN
A single i.p. injection of 100 mg/kg acrylamide monomer elevated the frequency of chromosome aberrations and micronucleated polychromatic erythrocytes in the bone marrow of male ICR mice. A positive relationship between frequency of micronuclei and dose of acrylamide was obtained in the dose range of 2 x 25, 2 x 50 and 2 x 100 mg/kg.
Asunto(s)
Acrilamidas/toxicidad , Aberraciones Cromosómicas , Acrilamida , Animales , Médula Ósea/efectos de los fármacos , Células de la Médula Ósea , Eritrocitos Anormales , Masculino , Ratones , Pruebas de MicronúcleosRESUMEN
Single oral dose of benzidine (300 mg/kg) and DCB (1000 mg/kg) to male ICR mice elicited positive response in the bone marrow micronucleus test. In the transplacental micronucleus test, the compounds were administered to pregnant females in the same manner. A significant increase in the frequency of micronuclei occurred in the fetal liver, but not in the bone marrow of mothers. The relative values of bone marrow and transplacental micronucleus tests for the prediction of carcinogenicity of these compounds is discussed.
Asunto(s)
3,3'-Diclorobencidina/toxicidad , Bencidinas/toxicidad , Médula Ósea/patología , Carcinógenos , Núcleo Celular/efectos de los fármacos , Hígado/patología , 3,3'-Diclorobencidina/administración & dosificación , Administración Oral , Animales , Bencidinas/administración & dosificación , Médula Ósea/efectos de los fármacos , Médula Ósea/embriología , Femenino , Feto , Hígado/efectos de los fármacos , Hígado/embriología , Masculino , Ratones , Ratones Endogámicos ICR , EmbarazoRESUMEN
The growth-promoting agents carbadox and olaquindox were active in the mouse transplacental micronucleus test, whereas cyadox was ineffective. Chemicals were administered p.o. and i.p. at a dose of 100 mg/kg and the effect was observed 18 h after treatment. The effects observed in fetal liver were parallel to those in maternal bone marrow, but fetal tissue was approximately 2-3 times more sensitive.
Asunto(s)
Carbadox/farmacología , Núcleo Celular/efectos de los fármacos , Quinoxalinas/farmacología , Administración Oral , Animales , Médula Ósea/efectos de los fármacos , Carbadox/administración & dosificación , Núcleo Celular/ultraestructura , Femenino , Feto/efectos de los fármacos , Inyecciones Intraperitoneales , Hígado/efectos de los fármacos , Intercambio Materno-Fetal , Ratones , Ratones Endogámicos ICR , Embarazo , Quinoxalinas/administración & dosificaciónRESUMEN
The clastogenicity of the growth-promoting agents, carbadox, olaquindox and cyadox, was examined by the metaphase analysis of chromosome aberrations in bone marrow of mice. The agents were administered by a stomach tube to male ICR mice 24 h before they were killed. Single-dose levels were 50, 100 and 200 mg/kg for carbadox; 200, 400, 600 and 800 mg/kg for olaquindox; and 400, 800 and 1200 mg/kg for cyadox. Carbadox was the most active; it induced chromosome aberrations even at a dose of 100 mg/kg. Olaquindox had about the same activity at a dose of 800 mg/kg. No chromosome-damaging effect of cyadox was observed even at a dose of 1200 mg/kg.
